-
Pelthos acquires head lice treatment assets for $1.8 million
-
Pelthos Therapeutics appoints Andrew Einhorn to board of directors
-
Pelthos signs pharmacy benefit manager deal for molluscum treatment
-
H.C. Wainwright Starts Pelthos Therapeutics (PTHS) at Buy
-
Roth/MKM Starts Pelthos Therapeutics (PTHS) at Buy
-
Pelthos Therapeutics (PTHS) PT Raised to $57 at Oppenheimer
-
Pelthos Therapeutics Inc. (PTHS) reported Q3 result
-
Pelthos Therapeutics acquires Xepi cream and raises $18 million
-
Pelthos launches patient advocacy campaign for molluscum skin infection
-
Oppenheimer Starts Pelthos Therapeutics (PTHS) at Outperform
-
Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss of $5.38
-
Ligand Pharma (LGND) Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

